Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT ZENTALIS PHARMACEUTICALS, INC.

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL)
Listen to this Section


$3.74
-0.2150 ( -5.44% ) 372.5K

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Market Data


Open $3.74
Previous Close $3.95
Volume 372.5K
Market Cap $281.19M
Day Range $3.72 - $4.01
52 Week Range $1.13 - $6.95
Shares Outstanding 71.19M
Change % -5.44%
Net Change ▼ -0.2150
Insider Ownership -0.40%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2020
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -1,374,014.00

Date Type Amount Purchased Purchaser
2023-10-06 Sale -5085.00 Bunker Kevin D.
2023-10-06 Sale -4594.00 Epperly Melissa B,
2023-09-13 Sale -5000.00 Skvarka Jan

SEC Filings


Form Type Description Pages Date
8-k 8K-related 53 Nov 10, 2025
10-q Quarterly Reports 75 Nov 10, 2025
4 Insider transactions 1 Oct 01, 2025
3 Insider transactions 3 Sep 22, 2025
8-k 8K-related 15 Aug 26, 2025
8-k 8K-related 53 Aug 06, 2025
10-q Quarterly Reports 75 Aug 06, 2025
4 Insider transactions 1 Jun 18, 2025
4 Insider transactions 1 Jun 18, 2025
4 Insider transactions 1 Jun 18, 2025

Latest News


× Before browsing our site, please accept our cookies policy